Tags

Type your tag names separated by a space and hit enter

Insights into lncRNAs in Alzheimer's disease mechanisms.
RNA Biol. 2021 07; 18(7):1037-1047.RB

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the most common dementia among the elderly. The pathophysiology of AD is characterized by two hallmarks: amyloid plaques, produced by amyloid β (Aβ) aggregation, and neurofibrillary tangle (NFT), produced by accumulation of phosphorylated tau. The regulatory roles of non-coding RNAs (ncRNAs), particularly long noncoding RNAs (lncRNAs), have been widely recognized in gene expression at the transcriptional and posttranscriptional levels. Mounting evidence shows that lncRNAs are aberrantly expressed in AD progression. Here, we review the lncRNAs that implicated in the regulation of Aβ peptide, tau, inflammation, cell death, and other aspects which are the main mechanisms of AD pathology. We also discuss the possible clinical or therapeutic utility of lncRNA detection or targeting to help diagnose or possibly combat AD.

Links

PMC Free PDF

Authors+Show Affiliations

Li D
Institute on Aging and Brain Disorders, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, Hefei National Laboratory for Physical Sciences at the Microscale, School of Life Sciences, University of Science and Technology of China, Hefei, China. Neurodegenerative Disease Research Center, University of Science and Technology of China, Hefei, China. National Synchrotron Radiation Laboratory, University of Science and Technology of China, Hefei, China. CAS Key Laboratory of Brain Function and Disease, University of Science and Technology of China, Hefei, China.
Zhang J
Institute on Aging and Brain Disorders, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, Hefei National Laboratory for Physical Sciences at the Microscale, School of Life Sciences, University of Science and Technology of China, Hefei, China. Neurodegenerative Disease Research Center, University of Science and Technology of China, Hefei, China. CAS Key Laboratory of Brain Function and Disease, University of Science and Technology of China, Hefei, China.
Li X
Institute on Aging and Brain Disorders, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, Hefei National Laboratory for Physical Sciences at the Microscale, School of Life Sciences, University of Science and Technology of China, Hefei, China. Neurodegenerative Disease Research Center, University of Science and Technology of China, Hefei, China. CAS Key Laboratory of Brain Function and Disease, University of Science and Technology of China, Hefei, China.
Chen Y
Department of Neurology, The First Affiliated Hospital of University of Science and Technology of China, Hefei, China.
Yu F
Department of Neurology, The First Affiliated Hospital of University of Science and Technology of China, Hefei, China.
Liu Q
Institute on Aging and Brain Disorders, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, Hefei National Laboratory for Physical Sciences at the Microscale, School of Life Sciences, University of Science and Technology of China, Hefei, China. Neurodegenerative Disease Research Center, University of Science and Technology of China, Hefei, China. CAS Key Laboratory of Brain Function and Disease, University of Science and Technology of China, Hefei, China. CAS Center for Excellence in Animal Evolution and Genetics, Chinese Academy of Sciences, Kunming, China.

MeSH

Alzheimer DiseaseAmyloid beta-Protein PrecursorDementiaGene Expression RegulationHumansNeurofibrillary TanglesNeuronal PlasticityNeuronsPhosphorylationPlaque, AmyloidProtein AggregatesRNA, Long NoncodingRNA, MessengerSignal TransductionTranscription, Genetictau Proteins

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

32605500

Citation

Li, Dingfeng, et al. "Insights Into lncRNAs in Alzheimer's Disease Mechanisms." RNA Biology, vol. 18, no. 7, 2021, pp. 1037-1047.
Li D, Zhang J, Li X, et al. Insights into lncRNAs in Alzheimer's disease mechanisms. RNA Biol. 2021;18(7):1037-1047.
Li, D., Zhang, J., Li, X., Chen, Y., Yu, F., & Liu, Q. (2021). Insights into lncRNAs in Alzheimer's disease mechanisms. RNA Biology, 18(7), 1037-1047. https://doi.org/10.1080/15476286.2020.1788848
Li D, et al. Insights Into lncRNAs in Alzheimer's Disease Mechanisms. RNA Biol. 2021;18(7):1037-1047. PubMed PMID: 32605500.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Insights into lncRNAs in Alzheimer's disease mechanisms. AU - Li,Dingfeng, AU - Zhang,Juan, AU - Li,Xiaohui, AU - Chen,Yuhua, AU - Yu,Feng, AU - Liu,Qiang, Y1 - 2020/07/14/ PY - 2020/7/2/pubmed PY - 2022/1/1/medline PY - 2020/7/2/entrez KW - Alzheimer’s disease KW - Aβ KW - LncRNAs KW - tau SP - 1037 EP - 1047 JF - RNA biology JO - RNA Biol VL - 18 IS - 7 N2 - Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the most common dementia among the elderly. The pathophysiology of AD is characterized by two hallmarks: amyloid plaques, produced by amyloid β (Aβ) aggregation, and neurofibrillary tangle (NFT), produced by accumulation of phosphorylated tau. The regulatory roles of non-coding RNAs (ncRNAs), particularly long noncoding RNAs (lncRNAs), have been widely recognized in gene expression at the transcriptional and posttranscriptional levels. Mounting evidence shows that lncRNAs are aberrantly expressed in AD progression. Here, we review the lncRNAs that implicated in the regulation of Aβ peptide, tau, inflammation, cell death, and other aspects which are the main mechanisms of AD pathology. We also discuss the possible clinical or therapeutic utility of lncRNA detection or targeting to help diagnose or possibly combat AD. SN - 1555-8584 UR - https://www.unboundmedicine.com/medline/citation/32605500/Insights_into_lncRNAs_in_Alzheimer's_disease_mechanisms_ DB - PRIME DP - Unbound Medicine ER -